Translating Science into Practice: Key Takeaways From RAD 2026

At the Revolutionizing Atopic Dermatitis (RAD) 2026 meeting in Nashville, Tennessee, Raj Chovatiya, MD, PhD, MSCI, associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, highlighted the importance of connecting advances in immunology and disease mechanisms with practical patient care.

As a co-chair of RAD 2026 alongside Jonathan Silverberg, MD, PhD, MPH, professor of dermatology at the George Washington University School of Medicine and Health Sciences, Chovatiya reflected on the meeting’s focus on the rapidly evolving understanding of atopic dermatitis (AD), from foundational disease biology to emerging treatment strategies and multidisciplinary approaches. Over the course of the 3-day conference, attendees explored new clinical data, updated analyses of existing therapies, and evolving perspectives on how dermatology providers can optimize care for patients across age groups.

Chovatiya emphasized that one of the defining goals of RAD is to provide clinicians with both a detailed understanding of the science behind AD and a broader perspective on how those discoveries translate into everyday practice. He encouraged dermatology providers interested in deepening their knowledge of disease mechanisms, therapeutic decision-making, and the future of AD management to attend next year’s meeting, along with future RAD events.

“If you want to understand the mechanisms, the science, and the clinical implications of dealing with atopic dermatitis…this is the meeting,” Chovatiya told Dermatology Times. “It's really a chance for you to think about everything on a granular level and a 30,000-foot level about your patients with AD across all ages.”

One session he highlighted was the conference’s opening discussion, which focused on the evolution of inflammation, particularly type 2 inflammation, across atopic and allergic diseases. The session brought together perspectives from dermatology, allergy, and basic and translational science to examine how understanding of immune pathways has advanced while also identifying remaining gaps in knowledge.

According to Chovatiya, the most exciting developments in dermatology as of late have come from the increasingly close relationship between scientific discovery and clinical application. Advances in immunology have allowed researchers to identify new potential treatment targets, but translating those discoveries into effective therapies requires careful investigation and real-world evaluation.

He noted that not every promising scientific concept ultimately becomes a successful therapy, but the process of studying treatments in clinical practice provides valuable insights that guide future innovation. Understanding which approaches succeed, which do not, and why allows researchers to refine therapeutic strategies and develop more effective interventions.

For Chovatiya, the continued evolution of AD care represents an ongoing partnership between science and medicine. As researchers learn more about the mechanisms driving disease, clinicians gain new opportunities to personalize treatment and improve outcomes for patients living with this chronic inflammatory condition.

Missed our coverage of Revolutionizing Atopic Dermatitis 2026? Click here!